Related Experiment Video

Updated: Jun 4, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Sphingosine kinase 1 is a relevant molecular target in gastric cancer

Thorsten Fuereder1, Doris Hoeflmayer, Agnes Jaeger-Lansky

  • 1Department of Clinical Pharmacology, Medical University, Vienna, Austria.

Anti-Cancer Drugs
|March 2, 2011
PubMed

Insights

Sphingosine kinase 1 (Sphk1) inhibition shows potent anti-gastric cancer activity in vitro, increasing apoptosis and reducing tumor growth. However, in vivo delivery challenges limit its current therapeutic application for solid tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Sphingosine kinase 1 (Sphk1) is overexpressed in gastric cancer, correlating with poor prognosis.
  • The precise biological role of Sphk1 in gastric cancer progression remains largely undefined.
  • Sphk1's involvement in cell transformation and tumor growth suggests its potential as a therapeutic target.

Purpose of the Study:

  • To investigate the functional significance of Sphk1 as a molecular target in gastric cancer.
  • To evaluate the efficacy of Sphk1 inhibition using antisense oligonucleotide (ASO) technology.
  • To assess the combined effects of Sphk1 inhibition and chemotherapy.

Main Methods:

  • Gastric cancer cell lines (MKN28, N87) were treated with Sphk1-targeting locked nucleic acid-antisense oligonucleotides (LNA-ASO).
  • In vitro assays assessed Sphk1 mRNA regulation, cell growth inhibition, and apoptosis.
  • In vivo studies utilized athymic nude mouse xenograft models treated with Sphk1 LNA-ASO.

Main Results:

  • Sphk1 LNA-ASO significantly reduced Sphk1 mRNA levels (approx. two-fold) in gastric cancer cells in vitro.
  • In vitro treatment led to a 1.6-fold increase in apoptosis and over 50% inhibition of cancer cell growth.
  • Combination therapy with doxorubicin demonstrated significant chemosensitization in vitro.
  • In vivo, Sphk1 LNA-ASO showed no significant mRNA target regulation or antitumor activity in xenograft models.

Conclusions:

  • Sphk1 inhibition demonstrates potent single-agent anti-cancer activity and synergistic effects with chemotherapy in vitro.
  • These findings highlight Sphk1 as a biologically relevant molecular target for gastric cancer.
  • Challenges in in vivo delivery of RNA therapeutics targeting Sphk1 to solid tumors require further investigation.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...